Medically reviewed by Marla Anderson, MD The first signs of metastatic breast cancer depend on where the cancer spreads from ...
NCCN—an alliance of leading cancer centers—publishes a new resource to inform people about the latest recommendations around ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and ...
A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially ...